Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21708765 | 0.83 | PLCG1 (0.33) | NPC1RAB9AGAAANO1MEN1 | |
| SCHEMBL21708795 | 0.83 | TAS1R3 (0.33) | TAS1R3TAS1R1 | |
| SCHEMBL21708790 | 0.82 | NPC1 (0.32) | NPC1RAB9AANO1KMT2A | |
| SCHEMBL21708771 | 0.80 | SMN1; SMN2 (0.34) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21656332 | 0.80 | POLB (0.36) | NPC1RAB9AGAABDKRB1SMN1; SMN2 | |
| SCHEMBL21631952 | 0.77 | PTGFR (0.39) | BDKRB1SMN1; SMN2PLCG1 | |
| SCHEMBL21708779 | 0.75 | NPC1 (0.33) | NPC1RAB9AGAAANO1TAS1R3 | |
| SCHEMBL21708740 | 0.74 | L3MBTL1 (0.32) | TAS1R3TAS1R1 | |
| SCHEMBL21708670 | 0.74 | MEN1 (0.36) | NPC1RAB9AGAATAS1R3TAS1R1 | |
| SCHEMBL21708706 | 0.73 | L3MBTL1 (0.32) | TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609869-A1 | SUBSTITUTED N-ARYLETHYL-2-ARYLQUINOLINE-4-CARBOXAMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2020-02-19 | — | — | EP | disclosed |